Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.48 |
| ▸ | IL1B | P01584 | 11/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 2/20 | 0.35 |
| ▸ | CCNH | P51946 | 2/20 | 0.35 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29155947 | 0.82 | CHEK2 (0.53) | NLRP3IL1BTNFKCNH2CHEK1 | |
| SCHEMBL30684875 | 0.82 | CHEK2 (0.53) | NLRP3IL1BTNFKCNH2CHEK1 | |
| SCHEMBL29326575 | 0.82 | IL1B (0.51) | NLRP3IL1BTNFKCNH2CHEK1 | |
| SCHEMBL30054441 | 0.81 | IL1B (0.53) | NLRP3IL1BTNFKCNH2CHEK1 | |
| SCHEMBL30684869 | 0.81 | IL1B (0.53) | NLRP3IL1BTNFKCNH2CHEK1 | |
| SCHEMBL29155909 | 0.81 | IL1B (0.53) | NLRP3IL1BTNFKCNH2CHEK1 | |
| SCHEMBL29326816 | 0.81 | IL1B (0.53) | NLRP3IL1BTNFKCNH2CHEK1 | |
| SCHEMBL29974705 | 0.80 | NLRP3 (0.56) | NLRP3IL1BTNFKCNH2CHEK1 | |
| SCHEMBL29326515 | 0.79 | NLRP3 (0.49) | NLRP3IL1BTNFKCNH2 | |
| SCHEMBL29326364 | 0.78 | NLRP3 (0.52) | NLRP3IL1BTNFKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885IL1B 11/4885TNF 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.